The United States represents the largest addressable cannabis market globally, despite the lingering complexities of federal prohibition. Publicly traded companies operating directly within the U.S. plant-touching sector generally list their shares on the Canadian Securities Exchange (CSE), NEO Exchange (Cboe Canada), or over-the-counter (OTC) markets to successfully navigate federal banking and exchange restrictions. These vertically integrated Multi-State Operators (MSOs) control their entire supply chains—from cultivation and extraction facilities to retail dispensary operations—building massive regional moats across limited-license states. Furthermore, U.S.-listed ancillary companies, real estate investment trusts, and pharmaceutical operators that do not directly touch state-legal recreational cannabis are permitted to list directly on major domestic exchanges such as the NASDAQ and NYSE.

The primary catalyst for these equities in 2026 remains the anticipated Schedule III reclassification, which will ease the 280E tax burden, legitimize extensive medical research, and potentially open the doors to U.S. major exchange listings for plant-touching operators in the future.

Table of Publicly Listed U.S. Cannabis Companies

Detailed Corporate Profiles: United States

Curaleaf Holdings operates as the largest cannabis company globally by total revenue, reporting annual figures of approximately $1.77 billion and commanding a market capitalization exceeding $10 billion. Operating a sprawling network of 158 dispensaries and numerous cultivation centers across 17 U.S. states, Curaleaf executes a highly aggressive, expansionary growth strategy. Beyond its domestic footprint, Curaleaf is aggressively expanding its international presence, taking full control of its European operations to supply medical cannabis to the United Kingdom and the broader European Union. The company’s diverse brand portfolio covers premium flower, vape hardware, edibles, and hemp-derived THC beverages, providing a multifaceted hedge against localized market fluctuations.

Trulieve Cannabis is a dominant vertically integrated player that traditionally commands an overwhelming market share in its home state of Florida. Generating $1.65 billion in annual revenue, Trulieve operates over 200 dispensaries nationwide, with expanding strategic hubs in Pennsylvania and Arizona. The company heavily emphasizes the medical cannabis sector, utilizing a strict “seed-to-sale” model to ensure product consistency. Trulieve’s robust cash flow and deep penetration in limited-license states make it a bellwether for the broader U.S. MSO space.

Green Thumb Industries (GTI), headquartered in Chicago, Illinois, generated $1.61 billion in annual revenue and maintains a formidable presence in 15 states with roughly 75 retail locations operating under the “Rise” and “Essence” banners. GTI manages the entire lifecycle of cannabis consumer packaged goods (CPG), cultivating recognizable brands like Rythm, Dogwalkers, Beboe, Incredibles, and Dr. Solomon’s. The company’s strategic focus on heavily populated, limited-license states has yielded strong profit margins and sustainable long-term growth.

Cresco Labs, founded in 2013, is renowned for its wholesale-first strategy, operating essentially as a major consumer packaged goods distributor. While it maintains a network of proprietary retail stores, its primary objective is maximizing shelf-space penetration across the nation’s dispensaries. Cresco’s brand portfolio, including Cresco, High Supply, and Good News, focuses on reliable, standardized formulations that appeal to both recreational and medicinal users across multiple states. The company consistently reports strong quarterly revenues, recently exceeding $151 million in a single quarter.

Verano Holdings operates as a premier multi-state operator, reporting $0.87 billion in annual revenue. The company is known for its portfolio of premium, luxury-positioned cannabis brands and its rapid expansion through highly strategic, targeted acquisitions across limited-license markets. Similarly, Ascend Wellness Holdings has built a highly focused footprint in the Midwest and East Coast of the United States, generating $0.71 billion in annual revenue by targeting densely populated areas transitioning to adult-use frameworks.

Glass House Brands focuses heavily on the highly competitive California market, differentiating itself through an unwavering commitment to sustainable, low-cost, high-yield agriculture. The company commands a massive 5.5 million square foot cultivation site in Southern California. Managing brands like Glass House Farms, Mama Sue Wellness, and Forbidden Flowers, the company recently overhauled its labor and production models to maximize capacity and reduce the cost per gram of high-quality flower, positioning itself as a wholesale titan in the West Coast supply chain.

Vireo Growth, Jushi Holdings, and TerrAscend represent the next tier of highly competitive, vertically integrated operators. Vireo Growth, reporting quarterly sales of $104.5 million, focuses on physician-led, science-based product development. Jushi Holdings operates a robust retail network generating $66.4 million per quarter, heavily focused on the Pennsylvania and Virginia markets. TerrAscend, posting $65.5 million in quarterly revenue, operates cultivation and retail assets across states like New Jersey, Maryland, and Michigan, while also maintaining a presence in Canada.

Jazz Pharmaceuticals represents the highest tier of pharmaceutical integration of cannabinoids, contrasting sharply with the consumer-packaged goods models of standard MSOs. As a global biopharmaceutical giant listed on the NASDAQ, Jazz’s entry into the cannabinoid space via the $7.2 billion acquisition of GW Pharmaceuticals anchors it as a heavyweight in cannabis equity ETFs. Its flagship cannabis-derived drug, Epidiolex, is an FDA-approved prescription medicine utilized to treat rare, severe forms of childhood epilepsy, such as Dravet syndrome and Lennox-Gastaut syndrome.

Innovative Industrial Properties (IIPR) provides the critical real estate infrastructure required for cannabis cultivation and processing, operating uniquely as a Real Estate Investment Trust (REIT) on the NYSE. Because traditional banking and lending are highly restricted for U.S. cannabis companies, IIPR’s sale-leaseback programs serve as a vital source of non-dilutive capital for major industry operators. The firm owns specialized greenhouses and manufacturing facilities across 19 states, generating over $69 million in quarterly revenue by leasing them back to state-licensed operators under long-term, triple-net agreements.

Ancillary operators provide the infrastructure that supports the entire industry without directly cultivating the plant. WM Technology (Weedmaps) is a leading cannabis technology platform providing B2C dispensary locators, consumer reviews, and B2B compliance software, acting as the digital infrastructure connecting consumers to dispensaries while generating $42.2 million quarterly. GrowGeneration Corp. and Hydrofarm Holdings supply the physical “picks and shovels” for commercial cannabis cultivation, operating massive supply chains for hydroponics, specialty lighting, and organic nutrients. Advanced Flower Capital (AFCG) operates as an institutional lender, providing structured debt financing to the cannabis sector. Turning Point Brands has successfully diversified its traditional tobacco and smoking accessories portfolio to heavily target the hemp-derived product market.

Canada pioneered the global cannabis industry by implementing full federal legalization of adult-use cannabis in 2018. The Canadian landscape is dominated by Licensed Producers (LPs) regulated rigorously by Health Canada. Because cannabis is federally legal, these companies possess the distinct advantage of trading on major international exchanges like the NASDAQ, NYSE, and TSX, granting them access to institutional capital pools unavailable to their American counterparts.

However, the Canadian domestic market has suffered heavily from structural oversupply, severe price compression, and fierce, ongoing competition from the entrenched illicit market. Consequently, the prevailing strategy for top-tier LPs in 2026 is extreme operational consolidation through mergers and acquisitions, alongside an aggressive pivot toward international medical exports (particularly to Europe and Australia). Furthermore, Canadian LPs are increasingly diversifying into adjacent consumer sectors, such as alcohol, craft brewing, and hemp-derived foods, to stabilize revenues.

Table of Publicly Listed Canadian Cannabis Companies

Detailed Corporate Profiles: Canada

Tilray Brands is a global juggernaut in both the medical and adult-use markets, formed from the historic reverse merger with Aphria. Generating an impressive $1.15 billion in annual revenue, Tilray operates extensive EU-GMP certified facilities in Portugal and Germany, supplying medical markets across Europe, Latin America, and Australia. Recognizing the margin compression in domestic Canadian cannabis, Tilray has aggressively diversified into the U.S. consumer packaged goods market. It owns the renowned hemp foods brand Manitoba Harvest and has acquired multiple craft beverage brands, including SweetWater Brewing and eight distinct brands from Anheuser-Busch. This diversification perfectly positions the company to launch THC-infused beverages in the United States immediately upon federal legalization.

Cronos Group, backed by a massive $1.8 billion strategic investment from tobacco giant Altria Group, boasts one of the strongest balance sheets in the sector. The company commands top-tier retail market share in Canada for cannabis flower and edibles through its Spinach and Cove brands. Internationally, Cronos operates the medical brand Peace Naturals, executing joint ventures and export agreements in Germany, Israel, and Australia. Furthermore, its robust cash position has allowed it to explore the U.S. hemp-derived CBD market and hold strategic options in U.S. operators like PharmaCann, ensuring it has an entry vector into the American market.

Canopy Growth Corporation was once the undisputed market capitalization leader of the initial cannabis boom. The company has since undergone massive structural reorganization to achieve profitability. Backed heavily by Constellation Brands, Canopy Growth maintains dominant brands in Canada and actively seeks to consolidate its U.S. ecosystem (Canopy USA) to immediately trigger integration upon federal permissibility. The company is deeply involved in industrial hemp, medical flower, and vaporizers, generating approximately $400 million in annual revenue while maintaining a vast global intellectual property portfolio.

SNDL Inc., formerly known as Sundial Growers, has radically transformed its business model to become the largest private-sector liquor and cannabis retailer in Canada. Generating over $104.8 million CAD in quarterly revenues, SNDL executes a retail-first acquisition strategy, aggressively acquiring dozens of dispensaries to completely control the point of sale. While the company continues to produce premium indoor cultivation brands like Top Leaf, Grasslands, and Palmetto, it derives significant long-term stability from its diversified retail operations and a dedicated investments segment that provides capital to other cannabis operators.

Aurora Cannabis has decisively shifted its focus heavily toward the high-margin global medical cannabis market, actively distancing itself from the volatile and hyper-competitive Canadian recreational sector. Aurora operates a sophisticated network of advanced EU-GMP certified facilities, enabling it to export medicinal cannabis to heavily regulated, high-paying markets in Europe and Australia. This strategy has stabilized the company, allowing it to generate steady quarterly revenues of $78.8 million CAD.

Organigram Holdings, known for its highly efficient, multi-level indoor cultivation facility in Moncton, New Brunswick, maintains some of the best cultivation economics and cost-per-gram metrics in Canada. Generating $80.1 million CAD per quarter, the company has focused heavily on product innovation in hash, edibles, and high-THC flower. Demonstrating a commitment to international expansion, Organigram recently acquired European assets, including a major investment in Sanity Group, to significantly expand its footprint in the burgeoning German medical market.

Village Farms International leverages decades of large-scale, high-tech greenhouse agricultural experience, translating its expertise in produce into massive, low-cost cannabis cultivation through its Pure Sunfarms subsidiary. Generating nearly $50 million quarterly, Village Farms is a top supplier of affordable, high-quality flower. High Tide Inc. dominates the retail and e-commerce space, operating the Canna Cabana retail chain and generating almost $150 million CAD per quarter. High Tide utilizes an innovative discount club model that drives intense customer loyalty and recurring revenue. Auxly Cannabis Group focuses strictly on Cannabis 2.0 products, developing highly successful lines of vaporizers, edibles, and concentrates, generating $40.1 million CAD quarterly.

The Australian cannabis sector is exclusively medicinal and stringently regulated by the Therapeutic Goods Administration (TGA) and the Office of Drug Control (ODC). Despite lacking a federally legal recreational market, the Australian capital markets (ASX) have successfully nurtured a highly dynamic ecosystem consisting of biotech innovators, telehealth platforms, and premium cultivators.

Australian cultivators are increasingly adopting PIC/S GMP standards. These standards are often considered more rigorous and comprehensive than standard EU-GMP, allowing Australian firms to export premium, pharmaceutical-grade flower to the world’s most stringent markets. Concurrently, domestic patient access pathways (such as the SAS-B scheme) have fueled explosive internal market growth. A Penington Institute report demonstrates that domestic spending on medicinal cannabis surged to approximately AU$400 million in the first half of 2024 alone, marking a massive increase in patient adoption.

Table of Publicly Listed Australian Cannabis Companies

Detailed Corporate Profiles: Australia

Vitura Health Ltd. (formerly Cronos Australia) operates a comprehensive digital health ecosystem that effectively bridges the critical gap between prescribers, pharmacies, and patients. Rather than focusing purely on agricultural cultivation, Vitura generates robust, recurring revenues through its highly successful Canview platform—an online prescribing, compliance, and distribution portal. Vitura also directly operates CDA Clinics and the telehealth service Cannadoc, alongside distributing plant-based medicines through its Burleigh Heads Cannabis (BHC) subsidiary. This vertically integrated platform approach shields the company from the inherent volatility of agricultural commodity price fluctuations.

Botanix Pharmaceuticals stands as the largest medical cannabis company on the ASX by market capitalization, boasting a valuation approaching AU$786 million. Based in Perth, Botanix operates strictly in the rigorous biopharmaceutical realm. The company leverages synthetic cannabidiol alongside its proprietary Permetrex skin-delivery technology to develop advanced dermatological therapies that treat conditions below the skin’s surface. Its clinical pipeline targets widespread conditions like moderate to severe acne, rosacea, atopic dermatitis, and antimicrobial solutions for staphylococcus aureus infections, positioning the firm closer to traditional biotech than standard cannabis operators.

Little Green Pharma (LGP) is a pioneering force in the Australian medicinal cannabis industry. The company operates world-class indoor cultivation and manufacturing facilities in both Western Australia and Denmark. This strategic, dual-hemisphere footprint allows LGP to supply pharmaceutical-grade products seamlessly into both the rapidly growing Australian domestic market and the lucrative European Union. LGP supplies products to patients, doctors, and pharmacists, remaining one of the most recognizable names in the European and Australian natural health sectors.

ECS Botanics aggressively sets itself apart through an unwavering commitment to regenerative agriculture, operating a massive organic, sun-grown cultivation facility in Victoria, Australia. By cultivating cannabis in living soil under the natural sun—rather than utilizing indoor synthetic substrates and artificial lighting—ECS produces highly resilient, terpene-rich, full-spectrum biomass at a fraction of the cost of traditional indoor facilities. Crucially, the company manufactures to PIC/S GMP and EU-GMP equivalent standards, positioning it as a leading, highly cost-effective B2B white-label supplier for both domestic and global export markets.

Cann Group Limited focuses heavily on the rigorous scientific breeding, cultivation, and manufacturing of medicinal cannabis. Operating state-of-the-art facilities, the company supplies raw biomass and finished medicinal products for patient access within Australia and for approved export pathways. Despite generating revenues of over $13 million AUD, the company continues to navigate the complex restructuring required to achieve profitability in a competitive agricultural landscape.

Neurotech International operates as a clinical-stage biotech firm focusing purely on novel cannabinoid-based therapies. The company is actively conducting trials to assess the efficacy of its proprietary full-spectrum cannabis extracts in treating pediatric neurological disorders, including Autism Spectrum Disorder (ASD), seeking to secure FDA designations for its therapies. Similarly, Zelira Therapeutics is a global therapeutic company focused on clinically validated branded cannabinoid medicines. With a robust portfolio targeting insomnia, autism (under the HOPE® brand), and chronic non-cancer pain, Zelira utilizes advanced delivery technologies to maximize the bioavailability of its formulations.

Bioxyne Limited, operating primarily through its subsidiary Breathe Life Sciences, is deeply involved in pharmaceutical manufacturing, wholesaling, and the distribution of own-brand (Dr Watson®) prescription medicines and health products. The company’s impressive footprint spans Australia, Europe, Japan, the UK, and the U.S., dealing in cannabinoids alongside investigational novel therapeutics like psilocybin and MDMA. Bod Science develops cannabis-derived health and skincare products, while IDT Australia provides essential contract drug manufacturing, licensed to process active pharmaceutical ingredients including high-CBD and high-THC solid oral and sterile liquid dosage forms.

Ecofibre Ltd. operates globally, advancing both nutraceuticals and high-performance industrial hemp fiber technologies. As an ASX-listed entity, it provides significant diversification to the Australian cannabis landscape by focusing on sustainable materials and hemp-derived health products rather than exclusively on medicinal cannabis.

The European cannabis market operates strictly on a medical and pharmaceutical axis, eschewing the rapid recreational rollouts seen in North America. Germany’s recent, historic regulatory modernization under the CanG law has removed cannabis from the strict Narcotics Act. This legislative overhaul has dramatically simplified the prescription process for physicians and sparked a massive surge in domestic medical demand, while also allowing for limited home cultivation and non-profit cannabis clubs. In the United Kingdom, specialized private clinics and sophisticated pharmaceutical manufacturers are meticulously building the foundation for a deeply regulated, prescription-only supply chain.

European publicly traded companies—listed primarily on the London Stock Exchange (LSE), the Alternative Investment Market (AIM), and the Frankfurt Stock Exchange (Xetra)—are primarily focused on securing EU-GMP distribution networks, advancing clinical biotech research, and developing high-tech extraction methodologies.

Table of Publicly Listed European Cannabis Companies

Detailed Corporate Profiles: Europe

SynBiotic SE operates as Germany’s premier publicly listed corporate group operating across the entire medical cannabis, CBD, and industrial hemp value chains. Utilizing a highly strategic “buy-and-build” investment approach, the holding company integrates various ventures to maintain rigorous quality management and control over cultivation, research and development, production, and retail distribution. Its subsidiary, Weeco, stands as one of the leading wholesale providers in the German medical market. Furthermore, SynBiotic aggressively targets the consumer wellness space with hemp-based dietary supplements and cosmetics under prominent brand names like Hempamed, Princess Stardust, and The Hempany.

Celadon Pharmaceuticals Plc is a trailblazing UK-based pharmaceutical company that achieved a historic regulatory milestone by becoming one of the first operators to receive explicit Home Office and MHRA licenses to cultivate and manufacture high-THC cannabis medicines within the UK. Operating a highly secure, 100,000 square foot indoor hydroponic facility featuring proprietary extraction and GMP-standard API manufacturing, Celadon focuses on developing breakthrough therapies for the estimated 8 million chronic pain sufferers in the UK who currently lack alternatives to opioids. The company also conducts conditionally approved clinical trials through its subsidiary, LVL Health, to build robust efficacy data and has successfully begun international commercial supply to the United States.

Kanabo Group Plc made history as the second medical cannabis company to list on the London Stock Exchange’s main market in 2021 and remains a pioneer in medical-grade vaporization technology. The company conducts extensive R&D in Israel to create high-quality cannabis extract formulas and non-smoking consumption solutions, ensuring precise, metered dosing for medical patients and CBD consumers across Europe.

Hellenic Dynamics Plc leverages the highly favorable agricultural climate of Northern Greece, operating a massive 195,506 square meter licensed facility near Thessaloniki. The company cultivates THC-dominant medical cannabis flowers exclusively for the export market, utilizing state-of-the-art cultivation systems to supply the rapidly expanding German and broader European pharmaceutical supply chains. Despite navigating complex legal and financial restructuring, the company’s sheer production capacity of over 54,000 kilograms per annum makes it a significant structural component of the European biomass market.

Futura Medical and Ananda Pharma, both listed on the LSE, are deeply entrenched in the biotechnology sub-sector. Futura utilizes its proprietary DermaSys platform to develop transdermal pain relief and sexual health products. Ananda Pharma focuses strictly on developing rigorous, cannabinoid-based clinical medicines targeting chronic pain and severe neurological conditions, aiming to bring fully licensed pharmaceutical drugs to market.

Israel possesses one of the most mature and scientifically advanced medical cannabis frameworks globally. The nation is characterized by extremely high domestic per-capita usage and an unrivaled global reputation as the epicenter of cannabinoid scientific research and clinical trials. Recognizing the economic importance of this sector, the Tel Aviv Stock Exchange (TASE) hosts a dedicated TA-Cannabis Index, reflecting the deep integration of agritech and biotech in the nation’s economy.

Table of Publicly Listed Israeli Cannabis Companies

Detailed Corporate Profiles: Israel

InterCure Ltd. is the undisputed commercial leader in the Israeli medical cannabis sector, consistently boasting the highest market capitalization on the TA-Cannabis index. The company executes a highly successful vertically integrated model, overseeing domestic cultivation, pharmaceutical manufacturing, and managing a vast network of dedicated medical dispensing pharmacies across the country. InterCure leverages strategic partnerships with major global brands, importing premium international genetics to satisfy the sophisticated demands of the domestic Israeli market while maintaining its own export capabilities.

BioHarvest Sciences Inc., while publicly listed in Canada, operates as an Israeli-based biotechnology marvel that fundamentally disrupts traditional agriculture. Over a span of 16 years and with investments exceeding $75 million, the company has developed a patented “Botanical Synthesis” platform. This plant cell culture technology is capable of growing active secondary metabolites (like specific cannabinoids and resveratrol) at an industrial scale without ever growing the actual plant itself. This technology promises unmatched consistency, purity, and environmental sustainability, making its proprietary botanical formulations highly sought after by global pharmaceutical, cosmeceutical, and nutraceutical partners.

Panaxia Israel, Seach Medical, and Tikun Olam Cannbit form the historical and operational bedrock of the Israeli supply chain. These entities focus intensely on clinical trials, GMP manufacturing, and exporting advanced medical formulations to European markets. Tikun Olam, in particular, is globally recognized for its pioneering observational studies and development of specific strains engineered for distinct medical indications.

As the global supply chain matures, operators recognize that high-cost indoor cultivation in North America and Europe is economically unviable for producing the massive volumes of extraction biomass required for pharmaceuticals. Consequently, low-cost agricultural jurisdictions in the Global South are rapidly scaling up GACP (Good Agricultural and Collection Practices) and EU-GMP infrastructure. These emerging hubs are designed to feed the European and Australian markets with high-quality, ultra-low-cost raw materials.

Table of Emerging Hub Public Cannabis Companies

Detailed Corporate Profiles: Emerging Hubs & Hemp Fiber

PharmaCielo Ltd., headquartered in Canada but operating exclusively in Rionegro, Colombia, leverages the perfect equatorial climate to drive high-efficiency, large-scale production. Utilizing 12 hectares of open-air greenhouses, PharmaCielo yields up to four full crop cycles annually, providing an exceptionally reliable supply of raw biomass. The company focuses entirely on high-volume extraction, producing pharmaceutical-grade CBD isolate, broad-spectrum distillate, and full-spectrum THC extracts. By combining Colombia’s ideal agricultural conditions with an advanced 2,000 m² Processing and Extraction Centre, PharmaCielo achieves incredibly low cost-per-gram metrics, positioning itself as a premier supplier for B2B global export.

Cilo Cybin Holdings Limited made history as the first Cannabis Special Purpose Acquisition Company (SPAC) to list on the Johannesburg Stock Exchange (JSE) AltX Board—and subsequently ascending to the JSE Main Board. Cilo Cybin represents the vanguard of African cannabis equities. The company was the first entity in South Africa to obtain both cultivation and manufacturing licenses. Operating a high-tech 2,500 square meter facility in Midrand, Cilo Cybin produces GMP-certified CBD, CBG, CBN, and THC distillates specifically destined for lucrative export markets in Australia, the UK, Europe, and Brazil.

The Thailand Transition: While Thailand dominated Asian headlines in 2022 by becoming the first Southeast Asian nation to decriminalize adult-use cannabis, the regulatory environment in 2026 has decisively shifted back toward a strictly controlled, medical-only model. The Royal Gazette recently formalized rigorous licensing criteria specifically governing the commercial processing and export of cannabis flower. Consequently, serious operators in Thailand—such as the GACP-certified Idol Farm and facilities backed by Austranna—are abandoning the retail dispensary model in favor of massive B2B commercial production. Thailand is rapidly professionalizing its supply chain to supply pharmaceutical markets in Japan, Australia, and Europe, leveraging its agricultural heritage to overcome early regulatory turbulence.

Industrial Hemp & Sustainable Fiber: Separate from the cannabinoid sector, the industrial hemp market is experiencing massive growth, driven by demand for sustainable building materials (hempcrete), bioplastics, and textiles. Panda Biotech, while currently operating as a massive private entity, is a world leader in zero-waste hemp processing. Collaborating with global apparel brands like Kontoor Brands (parent of Lee and Wrangler), Panda Biotech operates the largest industrial hemp decortication center in the United States, located in Texas, processing textile-grade fiber and premium cellulose. Similarly, European stalwarts like HempFlax Group provide essential sustainable insulation mats and construction materials.